These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8321836)

  • 1. Absorption, gastrointestinal transit, and tablet erosion of felodipine extended-release (ER) tablets.
    Abrahamsson B; Alpsten M; Hugosson M; Jonsson UE; Sundgren M; Svenheden A; Tölli J
    Pharm Res; 1993 May; 10(5):709-14. PubMed ID: 8321836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the intragastric location of extended release tablets on food interactions.
    Weitschies W; Wedemeyer RS; Kosch O; Fach K; Nagel S; Söderlind E; Trahms L; Abrahamsson B; Mönnikes H
    J Control Release; 2005 Nov; 108(2-3):375-85. PubMed ID: 16213057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of small intestinal transit and colon arrival times of non-disintegrating tablets administered in the fasted state.
    Pišlar M; Brelih H; Mrhar A; Bogataj M
    Eur J Pharm Sci; 2015 Jul; 75():131-41. PubMed ID: 25769525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and pharmacokinetics of Logimax, a new extended-release combination tablet of felodipine and metoprolol.
    Abrahamsson B; Edgar B; Lidman K; Wingstrand K
    Blood Press Suppl; 1993; 1():10-5. PubMed ID: 8173686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma concentration profiles and antihypertensive effect of conventional and extended-release felodipine tablets.
    Blychert E; Wingstrand K; Edgar B; Lidman K
    Br J Clin Pharmacol; 1990 Jan; 29(1):39-45. PubMed ID: 2404502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simulation of gastric lipolysis and prediction of felodipine release from a matrix tablet in the fed stomach.
    Diakidou A; Vertzoni M; Abrahamsson B; Dressman J; Reppas C
    Eur J Pharm Sci; 2009 May; 37(2):133-40. PubMed ID: 19429420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoscintigraphy confirms consistent tamsulosin release from a novel triple-layered tablet.
    Hodges LA; Sime KA; Creech LA; Connolly SM; Barclay ST; Kwon MC; Jeon BJ; Shim SM; Wang HS; Stevens HN; Park JS
    Int J Pharm; 2013 Sep; 454(1):41-6. PubMed ID: 23834829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal transit of model mini-tablet controlled release oral dosage forms in fasted human volunteers.
    Podczeck F; Course N; Newton JM; Short MB
    J Pharm Pharmacol; 2007 Jul; 59(7):941-5. PubMed ID: 17637188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behaviour and transit of tamsulosin Oral Controlled Absorption System in the gastrointestinal tract.
    Stevens HN; Speakman M
    Curr Med Res Opin; 2006 Dec; 22(12):2323-8. PubMed ID: 17257446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Diurnal Variation and Food on Gastrointestinal Transit of
    Kambayashi A; Sako K; Kondo H
    J Pharm Sci; 2020 Feb; 109(2):1020-1025. PubMed ID: 31600549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo evaluation of enteric-coated naproxen tablets using gamma scintigraphy.
    Wilding IR; Hardy JG; Sparrow RA; Davis SS; Daly PB; English JR
    Pharm Res; 1992 Nov; 9(11):1436-41. PubMed ID: 1475230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meal-induced acceleration of tablet transit through the human small intestine.
    Fadda HM; McConnell EL; Short MD; Basit AW
    Pharm Res; 2009 Feb; 26(2):356-60. PubMed ID: 18982248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scintigraphic evaluation of the in vivo performance of dry-coated delayed-release tablets in humans.
    Kambayashi A; Sako K; Kondo H
    Eur J Pharm Biopharm; 2020 Jul; 152():116-122. PubMed ID: 32380166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico, experimental, mechanistic model for extended-release felodipine disposition exhibiting complex absorption and a highly variable food interaction.
    Kim SH; Jackson AJ; Hunt CA
    PLoS One; 2014; 9(9):e108392. PubMed ID: 25268237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the effect of 3 different diets on the bioavailability of 2 sustained release theophylline matrix tablets.
    Gai MN; Isla A; Andonaegui MT; Thielemann AM; Seitz C
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):565-71. PubMed ID: 9455715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal transit of amoxicillin modified-release tablets and a placebo tablet including pharmacokinetic assessments of amoxicillin.
    Gottfries J; Svenheden A; Alpsten M; Bake B; Larsson A; Idström JP
    Scand J Gastroenterol; 1996 Jan; 31(1):49-53. PubMed ID: 8927940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal transit and release of mesalazine tablets in patients with inflammatory bowel disease.
    Healey JN
    Scand J Gastroenterol Suppl; 1990; 172():47-51. PubMed ID: 2353171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Felodipine clinical pharmacokinetics.
    Dunselman PH; Edgar B
    Clin Pharmacokinet; 1991 Dec; 21(6):418-30. PubMed ID: 1782737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal transit of Sinemet CR in healthy volunteers.
    Wilding IR; Davis SS; Melia CD; Hardy JG; Evans DF; Short AH; Sparrow RA
    Neurology; 1989 Nov; 39(11 Suppl 2):53-8. PubMed ID: 2685651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug absorption from nifedipine hydrophilic matrix extended-release (ER) tablet-comparison with an osmotic pump tablet and effect of food.
    Abrahamsson B; Alpsten M; Bake B; Jonsson UE; Eriksson-Lepkowska M; Larsson A
    J Control Release; 1998 Mar; 52(3):301-10. PubMed ID: 9743450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.